Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis

There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early commitment of beta-blockers (BBs), angiotensin recep...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kyriakos Goulas, Dimitrios Farmakis, Anastasia Constantinidou, Nikolaos P. E. Kadoglou
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-07-01
Edice:	Pharmaceuticals
Témata:	cardiotoxicity trastuzumab trastuzumab-induced cardiotoxicity (TIC) primary prevention beta-blockers (BBs) angiotensin receptor blockers (ARBs)
On-line přístup:	https://www.mdpi.com/1424-8247/16/7/983
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!